



# LUND UNIVERSITY

## Progress in methodology improved reporter gene assays used to identify ligands acting on orphan seven-transmembrane receptors.

Kotarsky, Knut; Nilsson, Niclas; Olde, Björn; Owman, Christer

*Published in:*  
Pharmacology and Toxicology

*DOI:*  
[10.1111/j.1600-0773.2003.pto930601.x](https://doi.org/10.1111/j.1600-0773.2003.pto930601.x)

2003

[Link to publication](#)

*Citation for published version (APA):*  
Kotarsky, K., Nilsson, N., Olde, B., & Owman, C. (2003). Progress in methodology improved reporter gene assays used to identify ligands acting on orphan seven-transmembrane receptors. *Pharmacology and Toxicology*, 93(6), 249-258. <https://doi.org/10.1111/j.1600-0773.2003.pto930601.x>

*Total number of authors:*  
4

### General rights

Unless other specific re-use rights are stated the following general rights apply:  
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00



## Progress in Methodology

# Improved Reporter Gene Assays Used to Identify Ligands Acting on Orphan Seven-Transmembrane Receptors

Knut Kotarsky, Niclas E. Nilsson, Björn Olde and Christer Owman

Division of Molecular Neurobiology, Department of Physiological Sciences, Wallenberg Neuroscience Center,  
S-221 84 Lund, Sweden

(Received June 25, 2003; Accepted September 27, 2003)

**Abstract:** Seven-transmembrane G-protein-coupled receptors play a central role in physiology by facilitating cell communication through recognition of a wide range of ligands. Even more important, they represent important drug targets. Unfortunately, for many of these receptors the endogenous ligands, and hence their functions, remain to be identified. These receptors are referred to as “orphan” receptors. A pre-requisite for the identification of ligands activating orphan receptors is powerful assay systems. Until now, reporter gene assays have not been in common use in this process. Here, we summarize our development of improved reporter gene assays. We optimized reporter gene assays in respect of (i) the promoter region of the construct, (ii) the reporter enzyme used, (iii) and the assay procedure. Furthermore, an unique fluorescence-based clone selection step was introduced, allowing rapid selection of the most sensitive reporter cell clones when establishing stable reporter cell lines. Mathematical formulae are provided to enable a simple and reliable comparison between different cell lines, when tested with a compound of interest. The resulting reporter cell lines responded in a very sensitive way to the stimulation of various test receptors. The reporter system was termed HighTRACE® (high-throughput reporter assay with clone election). Its high assay quality makes it suitable as a primary screening tool. Ligands for two recently unknown 7TM receptors were identified using the HighTRACE® system i.e., two cell surface free fatty acid receptors, GPR40 (FFA<sub>1</sub>R) and GPR43 (FFA<sub>2</sub>R). The identification was accomplished using a reverse pharmacology approach.

The seven-transmembrane (7TM), G-protein-coupled receptors comprise the largest family of cell surface receptors. A wide variety of molecules interact with and activate these receptors. The list of such ligands includes signaling molecules functioning as hormones, neurotransmitters, chemoattractants, or molecules formed outside the body, such as odorants, pheromones, nutrients, and even light. The ligands display widely different sizes (from larger proteins to small molecules) and belong to different chemical classes (lipids, amino acids, ions, or proteins). Despite these differences, the receptors show a common general architecture, including seven-transmembrane helices (recently reviewed by Lefkowitz 2000; Pierce *et al.* 2002; Schoneberg *et al.* 2002). It is generally assumed that they also function in a similar way, even when the ligand binding domains, or pockets, are not totally conserved. The only three-dimensional structure of a 7TM receptor known today from studies of its crystal structure is that of bovine rhodopsin. The structure was determined by X-ray crystallography; however, it shows the receptor in its inactive conformation (Palczewski *et al.* 2000). Attempts have been made to super-

impose other 7TM receptors onto the rhodopsin model *in silico* (Paterlini 2002). Differences in the primary sequences and in the ligand binding make receptor modeling difficult (Archer *et al.* 2003). Hence, the identification of ligands acting on 7TM receptors cannot be predicted from structural features but is still completely based on experimental methods, involving mass screening and other high throughput approaches.

### Orphan 7TM receptors

Seven-transmembrane, G-protein-coupled receptors play a central role in physiology since they facilitate cell communication in multicellular organisms by recognition of a broad range of ligands. They also represent important drug targets. Unfortunately, for many of these receptors the endogenous ligand(s) and, hence, their functions, remain to be identified. These receptors are referred to as “orphan” receptors.

The identification and characterization of such orphan, 7TM receptors have attracted much interest over the last decade. This focus on orphan 7TM receptors can be explained by two facts. Understanding cell communication, and eventually physiological mechanisms, requires both knowledge about the particular signaling mediators and

Author for correspondence: C. Owman, Molecular Neurobiology, BMC A12, S-221 84 Lund, Sweden (fax +46 46 22 20 567, e-mail Christer.Owman@mpny.lu.se).

their receptors. An even more important fact is that some fifty percent of all drugs in clinical use interact with 7TM receptors, making this family of receptors an important target for the development of drug candidates and the evaluation of lead compounds (Wilson *et al.* 1998). Hence, attempts to identify orphan 7TM receptors have not been driven by a purely academic interest, but have rather been carried out in a situation characterized by competition between academy and industry (Fujii *et al.* 2000; Hedrik *et al.* 2000; Hosoya *et al.* 2000; Howard *et al.* 2000; Kojima *et al.* 2000; Raddatz *et al.* 2000; Shan *et al.* 2000; Szekeres *et al.* 2000; Funes *et al.* 2002).

Estimations of the number of orphan 7TM receptors that vary between one hundred and several hundreds (Civelli *et al.* 2001; Howard *et al.* 2001; Im 2002; Szekeres 2002; Vassilatis *et al.* 2003). Such estimations usually do not include the odorant receptors. The total number of 7TM receptors has been estimated to 3–4% of all genes in humans and 5% in *Caenorhabditis elegans* (Bockart & Pin 1999; Bargmann 1998).

### Requirements on primary assay systems

In attempts to identify ligands acting on 7TM receptors the receptor protein is used as a “fishing tool”, either in binding assays or in functional tests. A plethora of different assay systems has been described in the literature. However, due to the tough requirements placed on the assay to be used in the initial characterization, systems actually applied for identification purposes are less numerous. Assays have to display a high reliability and quality, a property that is defined by a high Z-factor. The Z-factor combines the difference between background and signal, with the differences in the standard deviation of both values in a number between 0 and 1, where 1 stands for the theoretically ideal assay (Zhang *et al.* 1999). A Z-factor greater than 0.5 is required for an assay used as a primary screening tool (Zhang *et al.* 1999; Johnston 2002).

Assay systems used as a primary screening tool, apart from reporter gene assays (Hill *et al.* 2001; Kotarsky *et al.* 2003a), include methods to detect changes in the intracellular  $\text{Ca}^{2+}$  concentration (Tanahashi *et al.* 1990; Button & Brownstein 1993; Tryselius *et al.* 2000; Kotani *et al.* 2001; Niedernberg *et al.* 2003), binding assays (Wang *et al.* 2001), as well as assays based on yeast cells (Chambers *et al.* 2000; Brown *et al.* 2003) and on *Xenopus* oocytes (Bachner *et al.* 1999; Heise *et al.* 2000). The techniques used as primary screening tools have been reviewed recently (Hill *et al.* 2001; Szekeres 2002).

### Reporter gene assays

A widely used screening approach is the reporter gene technology (for review see Hill *et al.* (2001) and Naylor (1999)). It requires a DNA-based reporter construct, which usually consists of a promoter and a reporter gene, that are stably integrated into the genome of the cell. The transcriptional activity of the reporter gene is eventually regulated via the

intracellular signal transduction mechanisms by the receptor present on the cell membrane. The receptor can be either endogenously expressed or in a recombinant form.

Early reporter constructs contained whole gene promoters, which were regulated upon various stimuli (Vorabergger *et al.* 1991; Weyer *et al.* 1993; Stratowa *et al.* 1995). An increasing knowledge about, e.g., transcription factor binding sites and signaling pathways lead to the use of reporter constructs containing one or several copies of a response motif in their promoters (Sista *et al.* 1994; Chen *et al.* 1995; Boss *et al.* 1996). Certain transcription factors that are activated in response to the stimulation of different signaling pathways by the different G-proteins (table 1) can interact with specific response motifs. For example, receptors coupling to  $\text{G}\alpha_s$  activation have usually been monitored with reporter constructs containing cAMP-responsive elements (CRE) (Chen *et al.* 1995). Activation of  $\text{G}\alpha_q$  and  $\text{G}\alpha_i$ -coupled receptors has been performed using promoters which contain either TPA-response elements (TRE) (Sista *et al.* 1994, Kotarsky *et al.* 2001), serum response elements (Lin *et al.* 2002), nuclear factor of activated T-cells (NFAT) response elements (Zlokarnik *et al.* 1998; Kunapuli *et al.* 2003), or nuclear factor  $\kappa\text{B}$  (NF- $\kappa\text{B}$ ) response elements (Moon *et al.* 2001; Kotarsky *et al.* 2003a).

### Advantages and limitations of reporter gene assays.

Reporter gene assays have been used in numerous pharmaceutical studies investigating full or partial agonists, antagonists or inverse agonists (Hill *et al.* 2001; Johnston 2002). They are well suited to identify second messenger pathways and signaling cascades down-stream from the receptor to the nucleus (Gonzalez & Negulescu 1998). They have been applied to the process of “de-orphanization”, as primary or secondary screening tools (Briscoe *et al.* 2003; Kawamata *et al.* 2003). Reporter gene assays are well suited for high-throughput screening approaches in various assay formats (Hill *et al.* 2001).

However, the application of reporter gene assays is limited by certain features inherent to the assay itself. In order to establish a reporter gene assay, cells need to be stably transfected with several constructs. Stable integration of the reporter construct is a prerequisite for an efficient clonal selection (Kotarsky *et al.* 2001 & 2003a). In order for the test cells to produce the reporter enzyme an incubation time at 37°C of several hours is unavoidable. A potential interaction with other steps in the signaling cascade may be possible under that time and has to be excluded by appropriate controls. The signal amplification in reporter gene assays may change signaling behaviour of low-efficacy agonists, which may instead appear as full agonists. Even here appropriate controls, as an internal standard (Kotarsky *et al.* 2003b) that fully activates the reporter will be of great value.

### Optimization of the promoter region.

Our interest in 7TM receptors, displaying a high degree of sequence similarity to receptors for inflammatory mediators in

Table 1.

Some transcription factors and their response motifs activated by 7TM receptors.

Transcription factor	Response element	Activated by	Reference
CREB family	CRE	G $\alpha_s$	(Chen <i>et al.</i> 1995)
AP-1 (Fos and Jun)	TRE	G $\alpha_q$ , G $\alpha_i$	(Sista <i>et al.</i> 1994)
Serum response factor	SRE	G $\alpha_{12}$ , G $\alpha_{13}$ , G $\alpha_{q/11}$	(Lin <i>et al.</i> 2002; Suzuki <i>et al.</i> 2003)
NF- $\kappa$ B	NF- $\kappa$ B	All except G $\alpha_s$	(Ye 2001)
STAT	STAT	?	(Pelletier <i>et al.</i> 2003)
NFAT	NFAT	G $\alpha_q$	(Boss <i>et al.</i> 1996)

Question mark indicates that G-protein involvement is controversial.

the rhodopsin family, led us to use response motifs that were sensitive to  $\text{Ca}^{2+}$  elevation and mitogen-activated protein kinase (MAPK) activation. Primary attempts were made with constructs containing TPA responsive motifs (Kotarsky *et al.* 2001). TPA (12-O-tetradecanoylphorbol-13-acetate) is a phorbol ester that stimulates protein kinase C. Constructs containing 1, 5, and 9 response motifs in front of either a minimal FOS or minimal CMV (cytomegalovirus) promoter were transiently transfected into various cell lines. HeLa cells turned out to be a cell line showing the highest increase in luciferase activity when stimulated with phorbol ester. Reporter constructs containing 9 response motifs resulted in the highest increase of luciferase activity after this stimulation. Therefore, stable reporter cell lines were established with constructs containing 9 TRE. While constructs equipped with the minimal FOS promoter displayed a smaller overall signal than the CMV construct, the relative increases upon stimulation were substantially higher in the former constructs.

The first reporter construct used to establish stable cell lines was named pcFUS2 and contained 9 so-called TRE and a minimal CMV promoter (fig. 2). It was used for the construction of the HeLa HF1 reporter cell line.

The use of consensus response elements in the promoters of reporter gene constructs, rather than complete promoters of genes, had been introduced earlier (Chen *et al.* 1995; Boss *et al.* 1996). Czernilofsky *et al.* (1998) tested constructs containing 3 and 6 TRE transfected into COS cells, and recognized an increase in signal amplification in the latter constructs.

The promoter region was further optimized in an approach to expand the applicability of the reporter vector described (Kotarsky *et al.* 2003a). Multiple copies of a newly designed response motif were included into the reporter construct, which contained the consensus motifs of NF- $\kappa$ B and STAT binding sites. The reporter vector was also equipped with the minimal FOS promoter; it was named pcFUS3 (fig. 2) and was used for the construction of HeLa HFF11 cells. Reporter constructs containing two different kinds of transcription factor consensus motifs in their promoters have also been accomplished by Fitzgerald *et al.* (1999) by combining three multiple response element with a cAMP response element.

#### Choice of the reporter enzyme.

A useful reporter enzyme should display little or no background in eukaryotic cells and, in order to facilitate clone

selection, it should exhibit a single cell resolution. Luciferases, which are often used as reporters, do not have any internal background in mammalian systems and are, hence, very useful in plate-reader formats. However, luciferase activity is usually analyzed in lysed cells. Detection at a single cell level is not convincing and requires substrate loading of the cells (Craig *et al.* 1991; Greer & Szalay 2002).

In order to analyze reporter gene activity at a single cell level,  $\beta$ -galactosidase and  $\beta$ -lactamase have been used (Fiering *et al.* 1991; Zlokarnik *et al.* 1998; Knapp *et al.* 2003). Both require loading cells with substrate molecules, which are then converted into fluorescent products through the activity of the reporter enzyme. Besides this, cells have an intrinsic fluorescent background which makes these techniques less sensitive when used in a plate reader. In case of the  $\beta$ -lactamase assay, this problem has been addressed by using the ratio of two fluorescence wavelengths, rather than absolute changes in the fluorescence signal (Kunapuli *et al.* 2003; Zlokarnik *et al.* 1998).




Fig. 1. The cloning and selection procedures when establishing reporter cell lines for the described HighTRACE® reporter gene assays.

Green-fluorescent protein (GFP), on the other hand, displays an intrinsic fluorescent property due to its three-dimensional structure. This builds up a fluorophore consisting of three amino acids in tight proximity to each other (Prasher *et al.* 1992; Cody *et al.* 1993). A variety of GFP variants with different absorption and emission spectra have been described (Barak *et al.* 1997; Miyawaki *et al.* 1997; Kain 1999; Lenkei *et al.* 2000; Nagai *et al.* 2001). GFP is easily detected at a single cell level using fluorescence microscopy or flow cytometry, and it has also been used in plate-reader assays (Barak *et al.* 1997; Kain 1999). However, due to the intrinsic fluorescence of the cells the signal windows are rather small (Ghose *et al.* 1999).

In order to combine the advantageous properties of firefly luciferase and GFP, a chimeric protein based on a GFP-luciferase fusion gene was constructed (Kotarsky *et al.* 2001). The GFP gene was placed upstream of the firefly luciferase gene. When expressed in mammalian cells both partners retained their enzymatic properties. Reporter enzyme activity in transfected cells could easily be detected using either fluorescence microscopy, flow cytometry, or plate readers by a very high signal-to-background ratio and high Z-factors (Kotarsky *et al.* 2001 & 2003a).

#### Clone selection of reporter cell lines.

The single cell resolution displayed by the reporter enzyme has enabled an efficient clone selection procedure, which is either performed by fluorescence activated cell sorting (FACS) or by fluorescence microscopy. Instead of testing a large number of clones selected at random, cell clones resulting from a stable transfection were stimulated with a protein kinase C (PKC) activator, and cell clones showing a high EGFP (enhanced green-fluorescent protein) expression were subsequently picked, expanded, and retested (fig. 1). This clone selection step greatly simplified the identification of sensitive reporter cell clones. Whereas 90% to 95% of all cell clones selected with this method expressed firefly luciferase, cell clones selected in the conventional manner often failed to either express EGFP (85%), luciferase (72%),

or both (65%). Using the present approach it was sufficient to test 20–30 cell clones that expressed the highest level of EGFP after PMA stimulation in order to establish a well-responding reporter cell line. The best responding clone after three to four subsequent testings was chosen. The described reporter gene assays, including the described efficient clone selection, has been named HighTRACE® (high-throughput reporter assay with clone election) (Kotarsky *et al.* 2001).

Stable cell lines were established by the clone selection procedure described above. The cloning gave raise to either HF1 cell line (using pcFUS2), or the HFF11 cell line (using pcFUS3).

#### Example of 7TM receptors expressed in HighTRACE® reporter cell lines.

In further experiments the ability of several receptors to increase reporter enzyme activity was investigated after stimulation with the respective agonist. For this purpose the first leukotriene B4 receptor (BLT<sub>1</sub>), the fifth CC chemokine receptor (CCR5), and the rat  $\alpha_{1b}$  receptor were transfected into the HF1 reporter cell lines. These gave rise to the HF1pBLT1, HF1pCCR5, and HF1pR $\alpha_{1b}$  reporter cell lines.

The reporter cell lines were subsequently used in ligand stimulation experiments in order to obtain EC<sub>50</sub> values from the concentration-response curves. All tested reporter cell lines responded well to full agonist stimulation (CCR5/RANTES 15 times, rat  $\alpha_{1b}$  /epinephrine 50 times, and BLT<sub>1</sub>/LTB<sub>4</sub> 200 times), whereas control cells did not respond. The obtained EC<sub>50</sub> values were in good agreement with previously published results for these receptors (Yokomizo *et al.* 1997; Boie *et al.* 1999).

In contrast, other described reporter gene assays employ polyclonal cells or, more often, they test a small number of clones in a rather laborious process (Weyer *et al.* 1993; Sista *et al.* 1994; Goetz *et al.* 2000). The resulting reporter cell lines increased reporter protein activity at maximum stimulation by 3 to 20 times when stimulated with a strong PKC activator (Weyer *et al.* 1993; Sista *et al.* 1994).

In further experiments both cell lines, HF1 (containing pcFUS2) and HFF11 (containing pcFUS3) (fig. 2), were used in comparative studies. Experiments were performed using three different 7TM receptors as examples. The receptors were either recombinantly (complement C5a) or endogenously (CXCR4 and ATP-receptors) expressed in both cell lines. In all three cases it was found that the HFF11-based cell lines increased luciferase expression stronger in response to stimulation than the HF1-based cell lines (Kotarsky *et al.* 2003a).

Other receptors functionally expressed in HFF11 cells include the following 7TM receptors: BLT<sub>2</sub>R, CysLT<sub>2</sub>R, C3aR, PAR1 and the fatty acid receptors previously named GPR40, GPR41 and GPR43 (see below). Notably the design of the reporter enabled us to monitor also the activation of tyrosine kinase coupled receptors (e.g. EGF receptor).




Fig. 2. The design of the reporter constructs used to establish the stable cell lines HF1 (pcFUS2), HFF11 (pcFUS3), and HR36 (pcFUS3.sRL).




Fig. 3. Comparison of the assay procedures using a conventional reporter gene assay, based on an intracellular reporter, and a reporter gene assay based on a secreted reporter enzyme. RC: reporter cells.

#### Assay systems based on secreted reporter enzymes.

A further type of reporter construct was designed in order to simplify the assay procedure. Whereas firefly luciferase and many other reporter enzymes used in 96-well plate assays are based on their intracellular expression followed by analysis in cell lysates, other reporter enzymes, such as secreted alkaline phosphatase (Yang *et al.* 1997; Moon *et al.* 2001), or secreted luciferases (Thompson *et al.* 1990; Liu *et al.* 1997; Liu & Escher 1999; Tanahashi *et al.* 2001; Greer & Szalay 2002), can be analyzed in the supernatant of the cells. This simplifies the assay procedure in two ways: (i) it is not necessary to lyse the cells before analysis, which eliminates several steps in the cell handling, and (ii) normalization can be performed for each individual well before and after ligand stimulation (fig. 3). This will also improve assay quality.

While secreted alkaline phosphatase requires a heat-inactivation step in order to reduce the endogenous background, the luciferases can be analyzed immediately by adding their respective luciferins. The luciferin of the decapeptide *Vargula* is difficult to obtain commercially at reasonable costs; however, coelenterazine which may be used as luciferin for the *Renilla* luciferase provides an alternative. The *Gaussia* luciferase, which also uses coelenterazine as substrate, has recently been cloned and may offer a higher quantum yield than *Renilla* luciferase (Verhaegen & Christopoulos 2002).

Against this background, a reporter construct was de-

signed containing cDNA encoding two reporter enzymes: a secreted, genetically modified *Renilla* luciferase (Liu *et al.* 1997; Liu & Escher 1999), and a second intracellular reporter, composed of EGFP and firefly luciferase (fig 2). The expression of both enzymes was coupled using a short synthetic internal ribosomal entry site (IRES) (Edelman *et al.* 2000; Owens *et al.* 2001).

*Renilla* luciferase enzyme activity was easily detected in the cell supernatant. However, the expression of EGFP could not be detected using fluorescence microscopy or flow cytometry, not even in PMA-stimulated reporter cells. The cell lysate displayed small, though detectable, amounts of firefly luciferase activity using a plate luminometer. This indicates that the IRES directed the translation machinery to the second, intracellular reporter enzyme in a rather inefficient way. The amounts of intracellular reporter produced per cell were too small to allow for an efficient clone selection based on EGFP fluorescence.

Among 36 clones tested in an old-fashioned clone selection procedure, a clone designated HR36 was chosen for comparison of two different assay procedures. In the first approach, cells grown in 96-well plates were exposed to different ATP concentrations to stimulate endogenously expressed ATP receptors. In a second approach, cells grown in batch culture were suspended in an EDTA solution and added to the ligands present in a 96-well plate. *Renilla* luciferase activity was analyzed in the supernatant. The second approach simplifies assay performance, as it involves fewer steps in cell handling and at the same time it increases assay quality (fig. 3).

#### Strategies to identify orphan 7TM receptors

Generally, two different strategies have been used for the identification of orphan receptors. The pharmaceutical industry and some academic laboratories often use an approach known as reverse pharmacology. This implies the use of huge substance libraries, which are matched with recombinant orphan receptor libraries in attempts to find positive hits. Smaller laboratories, on the other hand, use a targeted approach often on "strange" receptors, over many years in laborious procedures to identify the ligand for a specific receptor. The second approach usually starts from a tissue extract as the source of the unknown ligand, and is often referred to as the orphan receptor strategy (Civelli *et al.* 1997, 1998, 1999 & 2001).

While the reverse pharmacology approach is mainly limited by the design of the substance and receptor libraries, the second approach relies completely on the presence of the ligand in a tissue extract. Ligand stability and low concentration of the ligand in a tissue extract of limited accessibility may further complicate ligand purification and subsequently identification.

To overcome these problems indirect approaches have been applied. Receptors with a high degree of sequence similarity are usually activated by similar ligands. Even the tissue distribution of the receptor may give certain clues

about the nature and function of the ligand. That in combination with the knock-out of the receptor in an animal model may provide information about physiological and patho-physiological processes the receptor is involved in.

### Application of HighTRACE® to the identification of fatty acid receptors

Using a reverse pharmacology approach we tested ten reporter cell lines, each expressing a different recombinant orphan 7TM receptor, in a screen aimed to identify possible fatty acid receptors. For this approach HFF11 reporter cell lines (Kotarsky *et al.* 2003a) were used. A schematic drawing is depicted in fig. 4.

A mock-transfected control cell line and reporter cell




Fig. 4. The performance of screening experiments that were used to deorphanize GPR40 and GPR43 using the HighTRACE® reporter gene assay. LE: light emission (in relative light units); NC: negative control (solvent); NV: normalized value; PC: positive control (e.g.  $10^{-6}$ M PMA); RC: reporter cells; RM: receptor M; TS: test substance.

lines each expressing a different orphan 7TM receptor were seeded into multi-well dishes and were stimulated with test substances ( $TS_{1,n}$ ), the negative control (solvent), or the positive control ( $10^{-6}$ M PMA). For each single well tested with a TS light production was normalized using equation 1 in fig. 4. After calculating the average  $\mu$  and standard deviation of the respective samples, the values derived from the TS tested on a cell line expressing a given receptor were compared with the values originated from a test cell line, which was mock-transfected and did not express any orphan 7TM receptor (fig. 4, equation 2). Equation 2 is used to calculate the Z-factor according to Zhang *et al.* (1999). An expanded use of the original formulae had been earlier suggested (Zhang *et al.* 1999). A Z-factor between 0.5 and 1 is strong evidence that  $TS_n$  has an effect on the cell line expressing receptor M; whereas a Z-factor below 0 will occur in the absence of a stimulating interaction between the TS and the orphan receptor. The here described approach might be used to compare multiple cell lines, increasing the reliability of the method.

In our experiment (Kotarsky *et al.* 2003b) the cell line expressing the orphan receptor, GPR40 (Sawzdargo *et al.* 1997), showed a significant increase in luciferase activity when stimulated with 50  $\mu$ M linoleic acid, with a Z-factor of 0.8.

Numerous fatty acids and their derivatives were subsequently tested using the GPR40-expressing HFF11 reporter cell line. Fatty acids with medium to long chain length and with different degree of saturation or hydroxylation all gave an increase in luciferase activity (table 2). However, short-chain fatty acids (C1-C4) had no effect on cells expressing GPR40 (up to 1 mM tested). Because of the activation of GPR40 by a wide range of fatty acids, along with its tissue distribution and its proposed physiological role, we suggested the name “free fatty acid receptor”, FFA<sub>1</sub>R, for this receptor.

The identification of GPR40 (FFA<sub>1</sub>R) as a receptor for medium-to-long chain free fatty acids was independently described by two other groups (Briscoe *et al.* 2003; Itoh *et al.* 2003), corroborating our main findings (table 2). Differences in the reported EC<sub>50</sub> values most probably reflect the different assay systems used for the identification. However, FFA<sub>1</sub>R seems to play an important physiological role since it modulates insulin secretion from pancreatic  $\beta$ -cells upon stimulation with free fatty acids (Itoh *et al.* 2003) and also responds to modern antidiabetic drugs (Kotarsky *et al.* 2003b) of the thiazolidinedione type (Cantello *et al.* 1994; Reginato *et al.* 1998).

A second orphan receptor, GPR43, activated by short-chain free fatty acids, was identified using the techniques described above (Nilsson *et al.* 2003). This receptor, mainly expressed on peripheral blood leukocytes (Nilsson *et al.* 2003; Senga *et al.* 2003), was most potently activated by acetate and propionate. Its existence may explain various effects of these short-chain fatty acids on immune cells under normal and pathophysiological conditions (Brown *et al.* 2003; Le Poul *et al.* 2003; Nilsson *et al.* 2003).

Table 2.

EC<sub>50</sub> values (in  $\mu$ M) calculated from concentration-response curves obtained from *in vitro* experiments using a recombinant HFF11 cell line expressing GPR40 (FFA<sub>1</sub>R) and stimulated with various fatty acids (Kotarsky *et al.* 2003b). EC<sub>50</sub> values published by Briscoe *et al.* (2003) and Itoh *et al.* (2003) were obtained using the FLIPR® (fluorometric imaging plate reader) equipment, which monitors intracellular Ca<sup>2+</sup> concentrations.

Trivial name	Abbreviation	EC <sub>50</sub> Kotarsky <i>et al.</i> (2003)	EC <sub>50</sub> Briscoe <i>et al.</i> (2003)	EC <sub>50</sub> Itoh <i>et al.</i> (2003)
Capric acid	10:0	12.6	14.1	43
Lauric acid	12:0	22.5	12.0	5.7
Myristic acid	14:0	30.3	14.5	7.7
Palmitic acid	16:0	143.2	5	6.8
Oleic acid	18:1	123.1	40.7	2.0
Elaidic acid	18:1 ( $\Delta 9$ )	149	6.9	4.7
Linoleic acid	18:2 ( $\Delta 9,12$ )	38.4	9.5	1.8
Linolenic acid	18:3 ( $\Delta 9,12,15$ )	27.1	12.5	2.0
$\gamma$ -Linolenic acid	18:3 ( $\Delta 6,9,12$ )	28.5	8.9	4.6
Arachidonic acid	20:4 ( $\Delta 5,8,11,14$ )	Not an agonist	12.0	2.4

### Conclusions

The identification of natural and surrogate ligands acting on 7TM receptors involve mainly cell-based assay systems. Hitherto, reporter gene assays have not been used extensively in this process. Oda *et al.* (2000) and Zhu *et al.* (2001) applied reporter gene techniques to the identification of a fourth histamine receptor (Oda *et al.* 2000; Zhu *et al.* 2001), and Kawamata *et al.* used a reporter gene assay to identify the first 7TM receptor responding to bile acids. In all these instances reporter gene assays were applied as primary screening tools, although they have also been used as secondary assays (An *et al.* 1997; Briscoe *et al.* 2003).

The design of improved reporter gene assays can be accomplished by optimizing the promoter region of the construct, the reporter enzyme used, and the assay procedure. Further, an efficient clone selection step allowing the election of the most sensitive reporter cell clones will increase the signal-to-background ratio markedly. As shown above in some examples, the test cell lines we have established responded very efficiently to stimulation of various cell surface receptors (Kotarsky *et al.* 2001 & 2003a). The amplification of the reporter enzyme activity was substantially larger than in any earlier described system, and its high assay quality makes it suitable as a primary screening tool. Reporter gene assays comprising an improved signal-to-background ratio and a high Z-factor have turned out to be useful for the identification of ligands acting on orphan 7TM receptors in a primary screening approach.

As presently exemplified, this led us to the discovery of the first and second cell surface, free fatty acid receptors, FFA<sub>1</sub>R and FFA<sub>2</sub>R (Kotarsky *et al.* 2003b; Nilsson *et al.* 2003). The identification of these two novel receptors provide an explanation for many physiological effects attributed to free fatty acids, that have hitherto remained unexplained and which previously have mainly been seen as energy sources and cell constituents. The activation of FFA<sub>1</sub>R by thiazolidinedione-type anti-diabetic drugs implies an important connection to type II diabetes, which is confirmed by the action of FFA<sub>1</sub>R on insulin secretion from pancreatic

$\beta$ -cells (Itoh *et al.* 2003). The receptor discovery will help to increase our understanding of the underlying mechanisms of this and other life-style diseases.

### Acknowledgements

This work was supported by Daimler-Benz-Foundation in Germany (grant to K.K.), GS Development, the Segerfalk Foundation, Crafoord Foundation, Ingabritt and Arne Lundberg Foundation, Kock Foundation, the Swedish Society for Medical Research, the Royal Physiographic Society in Lund, and the Swedish Research Council.

### References

- An, S., M. A. Dickens, T. Bleu, O. G. Hallmark & E. J. Goetzl: Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. *Biochem. Biophys. Res. Commun.* 1997, **231**, 619–622.
- Archer, E., B. Maigret, C. Escrieut, L. Pradayrol & D. Fourmy: Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? *Trends Pharmacol. Sci.* 2003, **24**, 36–40.
- Bachner, D., H. Kreienkamp, C. Weise, F. Buck & D. Richter: Identification of melanin concentrating hormone (MCH) as the natural ligand for the orphan somatostatin-like receptor 1 (SLC-1). *FEBS Lett.* 1999, **457**, 522–524.
- Barak, L. S., S. S. Ferguson, J. Zhang & M. G. Caron: A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. *J. Biol. Chem.* 1997, **272**, 27497–24500.
- Bargmann, C. I.: Neurobiology of the *Caenorhabditis elegans* genome. *Science* 1998, **282**, 2028–2033.
- Bockaert, J. & J. P. Pin: Molecular tinkering of G protein-coupled receptors: an evolutionary success. *Embo J.* 1999, **18**, 1723–1729.
- Boie, Y., R. Stocco, N. Sawyer, G. M. Greig, S. Kargman, D. M. Slipetz, G. P. O’Neil, T. Shimizu, T. Yokomizo, K. M. Metters & M. Abramowitz: Characterization of cloned guinea pig leukotriene B4 receptor: Comparison to its human ortholog. *Eur. J. Pharmacol.* 1999, **380**, 203–213.
- Boss, V., D. J. Talpade & T. J. Murphy: Induction of NFAT-mediated transcription by Gq-coupled receptors in lymphoid and non-lymphoid cells. *J. Biol. Chem.* 1996, **271**, 10429–10432.
- Briscoe, C. P., M. Tadayyon, J. L. Andrews, W. G. Benson, J. K. Chambers, M. M. Eilert, C. Ellis, N. A. Elshourbagy, A. S. Goetzl, D. T. Minnick, P. R. Murdock, H. R. Sauls, Jr., U. Shabon,

L. D. Spinage, J. C. Strum, P. G. Szekeres, K. B. Tan, J. M. Way, D. M. Ignar, S. Wilson & A. I. Muir: The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. *J. Biol. Chem.* 2003, **278**, 11303–11311.

Brown, A. J., S. M. Goldsworthy, A. A. Barnes, M. M. Eilert, L. Tcheang, D. Daniels, A. I. Muir, M. J. Wigglesworth, I. Kinghorn, N. J. Fraser, N. B. Pike, J. C. Strum, K. M. Steplewski, P. R. Murdock, J. C. Holder, F. H. Marshall, P. G. Szekeres, S. Wilson, D. M. Ignar, S. M. Foord, A. Wise & S. J. Dowell: The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J. Biol. Chem.* 2003, **278**, 11312–11319.

Button, D. & M. Brownstein: Aequorin-expressing mammalian cell lines used to report Ca<sup>2+</sup> mobilization. *Cell Calcium* 1993, **14**, 663–671.

Cantello, B. C., M. A. Cawthorne, G. P. Cottam, P. T. Duff, D. Haigh, R. M. Hindley, C. A. Lister, S. A. Smith & P. L. Thurlby: [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. *J. Med. Chem.* 1994, **37**, 3977–85.

Chambers, J. K., L. E. Macdonald, H. M. Sarau, R. S. Ames, K. Freeman, J. J. Foley, Y. Zhu, M. M. McLaughlin, P. Murdock, L. McMillan, J. Trill, A. Swift, N. Aiyar, P. Taylor, L. Vawter, S. Naheed, P. Szekeres, G. Hervieu, C. Scott, J. M. Watson, A. J. Murphy, E. Duzic, C. Klein, D. J. Bergsma, S. Wilson & G. P. Livi: A G protein-coupled receptor for UDP-glucose. *J. Biol. Chem.* 2000, **275**, 10767–10771.

Chen, W., T. S. Shields, P. J. Stork & R. D. Cone: A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways. *Anal. Biochem.* 1995, **226**, 349–354.

Civelli, O., H. P. Nothacker, A. Bourson, A. Ardati, F. Monsma & R. Reinscheid: Orphan receptors and their natural ligands. *J. Recept. Signal Transduct. Res.* 1997, **17**, 545–550.

Civelli, O., H. P. Nothacker & R. Reinscheid: Reverse physiology: discovery of the novel neuropeptide, orphanin FQ/nociceptin. *Crit. Rev. Neurobiol.* 1998, **12**, 163–176.

Civelli, O., H. P. Nothacker, Y. Saito, Z. Wang, S. H. Lin & R. K. Reinscheid: Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors. *Trends Neurosci.* 2001, **24**, 230–237.

Civelli, O., R. K. Reinscheid & H. P. Nothacker: Orphan receptors, novel neuropeptides and reverse pharmaceutical research. *Brain Res.* 1999, **848**, 63–65.

Cody, C. W., D. C. Prasher, W. M. Westler, F. G. Prendergast & W. W. Ward: Chemical structure of the hexapeptide chromophore of the Aequorea green-fluorescent protein. *Biochemistry* 1993, **32**, 1212–1218.

Craig, F. F., A. C. Simmonds, D. Watmore, F. McCapra & M. R. White: Membrane-permeable luciferin esters for assay of firefly luciferase in live intact cells. *Biochem. J.* 1991, **276**, 637–641.

Czernilofsky, A. P., A. Himmller, C. Stratowa, U. Weyer, H. Lamche & R. Schafer: Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path. *United States Patent* 1998, **Patent Number: 5,854,004**.

Edelman, G. M., R. Meech, G. C. Owens & F. S. Jones: Synthetic promoter elements obtained by nucleotide sequence variation and selection for activity. *Proc. Natl. Acad. Sci. USA* 2000, **97**, 3038–3043.

Fiering, S. N., M. Roederer, G. P. Nolan, D. R. Micklem, D. R. Parks & L. A. Herzenberg: Improved FACS-Gal: flow cytometric analysis and sorting of viable eukaryotic cells expressing reporter gene constructs. *Cytometry* 1991, **12**, 291–301.

Fitzgerald, L. R., I. J. Mannan, G. M. Dytko, H. L. Wu & P. Nambi: Measurement of responses from Gi-, Gs-, or Gq-coupled receptors by a multiple response element/cAMP response element-directed reporter assay. *Anal. Biochem.* 1999, **275**, 54–61.

Fujii, R., M. Hosoya, S. Fukusumi, Y. Kawamata, Y. Habata, S. Hinuma, H. Onda, O. Nishimura & M. Fujino: Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3. *J. Biol. Chem.* 2000, **275**, 21068–21074.

Funes, S., J. A. Hedrick, S. Yang, L. Shan, M. Bayne, F. J. Monsma, Jr. & E. L. Gustafson: Cloning and characterization of murine neuromedin U receptors. *Peptides* 2002, **23**, 1607–1615.

Ghose, S., H. Porzig & K. Baltensperger: Induction of erythroid differentiation by altered Galphai6 activity as detected by a reporter gene assay in MB-02 cells. *J. Biol. Chem.* 1999, **274**, 12848–12854.

Goetz, A. S., J. L. Andrews, T. R. Littleton & D. M. Ignar: Development of a facile method for high throughput screening with reporter gene assays. *J. Biomol. Screen.* 2000, **5**, 377–384.

Gonzalez, J. E. & P. A. Negulescu: Intracellular detection assays for high-throughput screening. *Curr. Opin. Biotechnol.* 1998, **9**, 624–631.

Greer, L. F., 3rd & A. A. Szalay: Imaging of light emission from the expression of luciferases in living cells and organisms: a review. *Luminescence* 2002, **17**, 43–74.

Hedrik, J. A., K. Morse, L. Shan, X. Qiao, L. Pang, S. Wang, T. Laz, E. L. Gustafson, M. Bayne & F. J. Monsma: Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U. *Molec. Pharmacol.* 2000, **58**, 870–875.

Heise, C. E., B. F. O'Dowd, D. J. Figueroa, N. Sawyer, T. Nguyen, D. S. Im, R. Stocco, J. N. Bellefeuille, M. Abramovitz, R. Cheng, D. L. Williams, Jr., Z. Zeng, Q. Liu, L. Ma, M. K. Clements, N. Coulombe, Y. Liu, C. P. Austin, S. R. George, G. P. O'Neill, K. M. Metters, K. R. Lynch & J. F. Evans: Characterization of the human cysteinyl leukotriene 2 receptor. *J. Biol. Chem.* 2000, **275**, 30531–30536.

Hill, S. J., J. G. Baker & S. Rees: Reporter-gene systems for the study of G-protein-coupled receptors. *Curr. Opin. Pharmacol.* 2001, **1**, 526–532.

Hosoya, M., T. Moriya, Y. Kawamata, S. Ohkubo, R. Fujii, H. Matsui, Y. Shintani, S. Fukusumi, Y. Habata, S. Hinuma, H. Onda, O. Nishimura & M. Fujino: Identification and functional characterization of a novel subtype of neuromedin U receptor. *J. Biol. Chem.* 2000, **275**, 29528–29532.

Howard, A. D., G. McAllister, S. D. Feighner, Q. Liu, R. P. Narlund, L. H. Van der Ploeg & A. A. Patchett: Orphan G-protein-coupled receptors and natural ligand discovery. *Trends Pharmacol. Sci.* 2001, **22**, 132–140.

Howard, A. D., R. Wang, S. S. Pong, T. N. Mellin, A. Strack, X. M. Guan, Z. Zeng, D. L. Williams, Jr., S. D. Feighner, C. N. Nunes, B. Murphy, J. N. Stair, H. Yu, Q. Jiang, M. K. Clements, C. P. Tan, K. K. McKee, D. L. Hreniuk, T. P. McDonald, K. R. Lynch, J. F. Evans, C. P. Austin, C. T. Caskey, L. H. Van der Ploeg & Q. Liu: Identification of receptors for neuromedin U and its role in feeding. *Nature* 2000, **406**, 70–74.

Im, D. S.: Orphan g protein-coupled receptors and beyond. *Jap. J. Pharmacol.* 2002, **90**, 101–106.

Itoh, Y., Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, H. Uejima, H. Tanaka, M. Maruyama, R. Satoh, S. Okubo, H. Kizawa, H. Komatsu, F. Matsumura, Y. Noguchi, T. Shinohara, S. Hinuma, Y. Fujisawa & M. Fujino: Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. *Nature* 2003, **422**, 173–176.

Johnston, P. A.: Cellular platforms for HTS: three case studies. *Drug Discov. Today* 2002, **7**, 353–363.

Kain, S. R.: Green fluorescent protein (GFP): applications in cell-based assays for drug discovery. *Drug Discov. Today* 1999, **4**, 304–312.

Kawamata, Y., R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, S. Fukusumi, Y. Habata, T. Itoh, Y. Shintani, S. Hinuma, Y. Fujisawa & M. Fujino: A G protein-coupled receptor responsive to bile acids. *J. Biol. Chem.* 2003, **278**, 9435–9440.

Knapp, T., E. Hare, L. Feng, G. Zlokarnik & P. Negulescu: Detection of beta-lactamase reporter gene expression by flow cytometry. *Cytometry* 2003, **51A**, 68–78.

Kojima, M., R. Haruno, M. Nakazato, Y. Date, N. Murakami, R.

Hanada, H., Matsuo & K. Kangawa: Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). *Biochem. Biophys. Res. Commun.* 2000, **276**, 435–438.

Kotani, M., M. Dethieux, A. Vandenbogaerde, D. Communi, J. M. Vanderwinden, E. Le Poul, S. Brezillon, R. Tyldesley, N. Suarez-Huerta, F. Vandeput, C. Blanpain, S. N. Schiffmann, G. Vassart & M. Parmentier: The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. *J. Biol. Chem.* 2001, **276**, 34631–34636.

Kotarsky, K., L. Antonsson, C. Owman & B. Olde: Optimized reporter gene assays based on a synthetic multifunctional promoter and a secreted luciferase. *Anal. Biochem.* 2003a, **316**, 208–215.

Kotarsky, K., N. E. Nilsson, E. Flodgren, C. Owman & B. Olde: A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. *Biochem. Biophys. Res. Commun.* 2003b, **301**, 406–410.

Kotarsky, K., C. Owman & B. Olde: A chimeric reporter gene allowing for clone selection and high-throughput screening of reporter cell lines expressing G-protein-coupled receptors. *Anal. Biochem.* 2001, **288**, 209–215.

Kunapuli, P., R. Ransom, K. L. Murphy, D. Pettibone, J. Kerby, S. Grimwood, P. Zuck, P. Hodder, R. Lacson, I. Hoffman, J. Inglese & B. Strulovici: Development of an intact cell reporter gene beta-lactamase assay for G protein-coupled receptors for high-throughput screening. *Anal. Biochem.* 2003, **314**, 16–29.

Le Poul, E., C. Loison, S. Struyf, J. Y. Springael, V. Lannoy, M. E. Decobecq, S. Brezillon, V. Dupriez, G. Vassart, J. Van Damme, M. Parmentier & M. Dethieux: Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cells activation. *J. Biol. Chem.* 2003, **278**, 25481–25489.

Lefkowitz, R.J. The superfamily of heptahelical receptors. *Nat. Cell Biol.*, 2000, **2**, 133–136.

Lenkei, Z., A. Beaudet, N. Chartrel, N. De Mota, T. Irinopoulou, B. Braun, H. Vaudry & C. Llorens-Cortes: A highly sensitive quantitative cytosensor technique for the identification of receptor ligands in tissue extracts. *J. Histochem. Cytochem.* 2000, **48**, 1553–1564.

Lin, K., D. Wang & W. Sadee: Serum response factor activation by muscarinic receptors via RhoA. Novel pathway specific to M1 subtype involving calmodulin, calcineurin, and Pyk2. *J. Biol. Chem.* 2002, **277**, 40789–40798.

Liu, J. & A. Escher: Improved assay sensitivity of an engineered secreted Renilla luciferase. *Gene* 1999, **237**, 153–159.

Liu, J., D. J. O’Kane & A. Escher: Secretion of functional Renilla reniformis luciferase by mammalian cells. *Gene* 1997, **203**, 141–148.

Miyawaki, A., J. Llopis, R. Heim, J. M. McCaffery, J. A. Adams, M. Ikura & R. Y. Tsien: Fluorescent indicators for  $\text{Ca}^{2+}$  based on green fluorescent proteins and calmodulin. *Nature* 1997, **388**, 882–887.

Moon, K. Y., B. S. Hahn, J. Lee & Y. S. Kim: A cell-based assay system for monitoring NF- $\kappa$ B activity in human HaCat transfected cells. *Anal. Biochem.* 2001, **292**, 17–21.

Nagai, T., A. Sawano, E. S. Park & A. Miyawaki: Circularly permuted green fluorescent proteins engineered to sense  $\text{Ca}^{2+}$ . *Proc. Natl. Acad. Sci. USA* 2001, **98**, 3197–3202.

Naylor, L. H.: Reporter gene technology: the future looks bright. *Biochem. Pharmacol.* 1999, **58**, 749–757.

Niedernberg, A., S. Tunaru, A. Blaukat, A. Ardati & E. Kostenis: Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. *Cell Signal.* 2003, **15**, 435–446.

Nilsson, N. E., K. Kotarsky, C. Owman & B. Olde: Identification of a free fatty acid receptor, FFA(2)R, expressed on leukocytes and activated by short-chain fatty acids. *Biochem. Biophys. Res. Commun.* 2003, **303**, 1047–1052.

Oda, T., N. Morikawa, Y. Saito, Y. Masuho & S. Matsumoto: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. *J. Biol. Chem.* 2000, **275**, 36781–36786.

Owens, G. C., S. A. Chappell, V. P. Mauro & G. M. Edelman: Identification of two short internal ribosome entry sites selected from libraries of random oligonucleotides. *Proc. Natl. Acad. Sci. USA* 2001, **98**, 1471–1476.

Palczewski, K., T. Kumada, T. Hori, C. A. Behnke, H. Motoshima, B. A. Fox, I. Le Trong, D. C. Teller, T. Okada, R. E. Stenkamp, M. Yamamoto & M. Miyano: Crystal structure of rhodopsin: A G protein-coupled receptor. *Science* 2000, **289**, 739–745.

Paterlini, M. G.: Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. *Biophys. J.* 2002, **83**, 3012–3031.

Pelletier, S., F. Duhamel, P. Coulombe, M. R. Popoff & S. Meloche: Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors. *Mol. Cell Biol.* 2003, **23**, 1316–1333.

Pierce, K. L., Premont, R. T. & Lefkowitz, R. J. Seven-transmembrane receptors. *Nat. Rev. Mol. Cell Biol.* 2002, **3**, 639–650.

Prasher, D. C., V. K. Eckenrode, W. W. Ward, F. G. Prendergast & M. J. Cormier: Primary structure of the *Aequorea victoria* green-fluorescent protein. *Gene* 1992, **111**, 229–233.

Raddatz, R., A. E. Wilson, R. Artymyshyn, J. A. Bonini, B. Borowsky, L. W. Boteju, S. Zhou, E. V. Kouranova, R. Nagorny, M. S. Guevarra, M. Dai, G. S. Lerman, P. J. Vaysse, T. A. Branchek, C. Gerald, C. Forray & N. Adham: Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. *J. Biol. Chem.* 2000, **275**, 32452–32459.

Reginato, M. J., S. T. Bailey, S. L. Krakow, C. Minami, S. Ishii, H. Tanaka & M. A. Lazar: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. *J. Biol. Chem.* 1998, **273**, 32679–32684.

Sawzdargo, M., S. R. George, T. Nguyen, S. Xu, L. F. Kolakowski & B. F. O’Dowd: A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. *Biochem. Biophys. Res. Commun.* 1997, **239**, 543–547.

Schoneberg, T., A. Schulz & T. Gudermann: The structural basis of G-protein-coupled receptor function and dysfunction in human disease. *Rev. Physiol. Biochem. Pharmacol.* 2002, **144**, 143–227.

Senga, T., S. Iwamoto, T. Yoshida, T. Yokota, K. Adachi, E. Azuma, M. Hamaguchi & T. Iwamoto: LSSIG is a novel murine leukocyte-specific GPCR that is induced by the activation of STAT3. *Blood* 2003, **101**, 1185–1187.

Shan, L., X. Qiao, J. H. Crona, J. Behan, S. Wang, T. Laz, M. Bayne, E. L. Gustafson, F. J. Monsma, Jr. & J. A. Hedrick: Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. *J. Biol. Chem.* 2000, **275**, 39482–39486.

Sista, P., S. Edmiston, J. W. Darges, S. Robinson & D. J. Burns: A cell-based reporter assay for the identification of protein kinase C activators and inhibitors. *Mol. Cell Biochem.* 1994, **141**, 129–134.

Stratowa, C., H. Machat, E. Burger, A. Himmeler, R. Schafer, W. Spevak, U. Weyer, M. Wiche-Castanon & A. P. Czernilofsky: Functional characterization of the human neurokinin receptors NK1, NK2, and NK3 based on a cellular assay system. *J. Recept. Signal. Transduct. Res.* 1995, **15**, 617–630.

Suzuki, N., S. Nakamura, H. Mano & T. Kozasa: Galphai 2 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF. *Proc. Natl. Acad. Sci. USA* 2003, **100**, 733–738.

Szekeress, P. G.: Functional assays for identifying ligands at orphan G protein-coupled receptors. *Receptors and Channels* 2002, **8**, 297–308.

Szekeress, P. G., A. I. Muir, L. D. Spinage, J. E. Miller, S. I. Butler, A. Smith, G. I. Rennie, P. R. Murdock, L. R. Fitzgerald, H. Wu,

L. J. McMillan, S. Guerrera, L. Vawter, N. A. Elshourbagy, J. L. Mooney, D. J. Bergsma, S. Wilson & J. K. Chambers: Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3. *J. Biol. Chem.* 2000, **275**, 20247–20250.

Tanahashi, H., T. Ito, S. Inouye, F. I. Tsuji & Y. Sakaki: Photoprotein aequorin: use as a reporter enzyme in studying gene expression in mammalian cells. *Gene* 1990, **96**, 249–255.

Tanahashi, Y., Y. Ohmiya, S. Honma, Y. Katsuno, H. Ohta, H. Nakamura & K. I. Honma: Continuous measurement of targeted promoter activity by a secreted bioluminescence reporter, Vargula hilgendorfii luciferase. *Anal. Biochem.* 2001, **289**, 260–266.

Thompson, E. M., S. Nagata & F. I. Tsuji: Vargula hilgendorfii luciferase: a secreted reporter enzyme for monitoring gene expression in mammalian cells. *Gene* 1990, **96**, 257–262.

Tryselius, Y., N. E. Nilsson, K. Kotarsky, B. Olde & C. Owman: Cloning and characterization of cDNA encoding a novel human leukotriene B(4) receptor. *Biochem. Biophys. Res. Commun.* 2000, **274**, 377–382.

Vassilatis, D. K., J. G. Hohmann, H. Zeng, F. Li, J. E. Ranchalis, M. T. Mortrud, A. Brown, S. S. Rodriguez, J. R. Weller, A. C. Wright, J. E. Bergmann & G. A. Gaitanaris: The G protein-coupled receptor repertoires of human and mouse. *Proc. Natl. Acad. Sci. USA* 2003, **100**, 4903–4908.

Verhaegen, M. & T. K. Christopoulos: Recombinant *Gaussia* luciferase. Overexpression, purification, and analytical application of a bioluminescent reporter for DNA hybridization. *Anal. Chem.* 2002, **74**, 4378–4385.

Vorabeger, G., R. Schafer & C. Stratowa: Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5'-regulatory region. Induction by cytokines and phorbol ester. *J. Immunol.* 1991, **147**, 2777–2786.

Wang, S., J. Behan, K. O'Neill, B. Weig, S. Fried, T. Laz, M. Bayne, E. Gustafson & B. E. Hawes: Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, mch-r2. *J. Biol. Chem.* 2001, **276**, 34664–34670.

Weyer, U., R. Schafer, A. Himmeler, S. K. Mayer, E. Burger, A. P. Czernilofsky & C. Stratowa: Establishment of a cellular assay system for G protein-linked receptors: coupling of human NK2 and 5-HT2 receptors to phospholipase C activates a luciferase reporter gene. *Receptors Channels* 1993, **1**, 193–200.

Wilson, S., D. J. Bergsma, J. K. Chambers, A. I. Muir, K. G. Fantom, C. Ellis, P. R. Murdock, N. C. Herrity & J. M. Stadel: Orphan G-protein-coupled receptors: the next generation of drug targets? *Brit. J. Pharmacol.* 1998, **125**, 1387–1392.

Yang, T. T., P. Sinai, P. A. Kitts & S. R. Kain: Quantification of gene expression with a secreted alkaline phosphatase reporter system. *Biotechniques* 1997, **23**, 1110–1114.

Ye, R. D.: Regulation of nuclear factor kappaB activation by G-protein-coupled receptors. *J. Leukoc. Biol.* 2001, **70**, 839–48.

Yokomizo, T., T. Izumi, K. Chang, Y. Takuwa & T. Shimizu: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. *Nature* 1997, **387**, 620–624.

Zhang, J. H., T. D. Chung & K. R. Oldenburg: A Simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen.* 1999, **4**, 67–73.

Zhu, Y., D. Michalovich, H. Wu, K. B. Tan, G. M. Dytko, I. J. Mannan, R. Boyce, J. Alston, L. A. Tierney, X. Li, N. C. Herrity, L. Vawter, H. M. Sarau, R. S. Ames, C. M. Davenport, J. P. Hieble, S. Wilson, D. J. Bergsma & L. R. Fitzgerald: Cloning, expression, and pharmacological characterization of a novel human histamine receptor. *Mol. Pharmacol.* 2001, **59**, 434–441.

Zlokarnik, G., P. A. Negulescu, T. E. Knapp, L. Mere, N. Burres, L. Feng, M. Whitney, K. Roemer & R. Y. Tsien: Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. *Science* 1998, **279**, 84–88.